Balestrini A E, Menzio A C, Cabral R, Feldman R, Mercogliano C, Flichtentrei D, Albera H P, Vazquez A
Eur J Clin Pharmacol. 1984;27(1):1-5.
In order to test the additional efficacy of the combination of a beta blocker (penbutolol 40 mg single dose) with molsidomine (2 mg single dose), a double blind cross-over trial was performed in 30 patients with stable angina pectoris. Stress tests were done before and 1 h after the beta blocker alone and the combination therapy. Some training effect could be detected on comparing results from the first and second days. Combined therapy showed a better response of resting systolic arterial pressure, resting and maximal diastolic pressure, heart rate gain (from rest to maximal effort) and particularly in the angina severity score. All of these variables changed significantly in comparison to the beta blocker alone, 46 out of 60 post-drug ergometric studies were negative; of the 14 positive tests, 11 followed the beta blocker and only 3 the combined therapy. The combination of a preload reducer molsidomine and a beta blocker may be adequate for patients only partially compensated or with cardiomegaly and/or a depressed ejection fraction.
为了测试β受体阻滞剂（单剂量喷布洛尔40毫克）与吗多明（单剂量2毫克）联合使用的额外疗效，对30例稳定型心绞痛患者进行了双盲交叉试验。在单独使用β受体阻滞剂和联合治疗前及治疗后1小时进行了应激试验。比较第一天和第二天的结果时可检测到一些训练效应。联合治疗在静息收缩压、静息和最大舒张压、心率增加（从静息到最大运动）方面显示出更好的反应，特别是在心绞痛严重程度评分方面。与单独使用β受体阻滞剂相比，所有这些变量均有显著变化，60项用药后测力计研究中有46项为阴性；在14项阳性试验中，11项在使用β受体阻滞剂后出现，只有3项在联合治疗后出现。对于仅部分代偿或有心脏扩大和/或射血分数降低的患者，预负荷降低剂吗多明与β受体阻滞剂的联合使用可能是合适的。
